Cepheid (NASDAQ:CPHD)

CAPS Rating: 3 out of 5

A molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the Clinical Molecular Diagnostic, Industrial and Biothreat markets.

Recs

0
Player Avatar fas9 (< 20) Submitted: 12/21/2007 1:37:30 PM : Outperform Start Price: $26.52 CPHD Score: +51.71

a solid company with products coming to market that have little to no competition, but pressing demand and need((rapid HPV staph infection testing . a must buy

Featured Broker Partners


Advertisement